What Is Pingyangmycin? Definition and What Research Reports

Definition

Pingyangmycin is a naturally derived glycopeptide antibiotic belonging to the bleomycin family, produced by microbial fermentation of a Streptomyces verticillus strain and widely referred to in the literature as bleomycin A5. Like other bleomycins, it is a complex glycosylated peptide-based molecule rather than a short synthetic amino-acid sequence, and it is handled in the published record as an injectable antitumour and sclerosing agent rather than as a metabolic or signalling peptide. The name is conventionally traced to Pingyang, the locality in China associated with the producing strain from which the compound was first isolated. Most of the clinical literature indexed under this term comes from oral and maxillofacial surgery, dermatology, and interventional radiology, where the compound has been studied as an intralesional injection for vascular and lymphatic lesions and for several benign proliferative skin conditions.

Molecular Class and Origin

Pingyangmycin sits in the same structural family as bleomycin A2 and the mixed bleomycin preparations used in oncology. These molecules combine a peptide backbone with carbohydrate and metal-binding components, which is why they are classified as glycopeptides. Because the molecule is a fermentation product of a soil bacterium rather than a laboratory-assembled sequence, it is chemically and functionally distinct from the synthetic research peptides — such as growth-hormone secretagogues or melanocortin analogues — that dominate most peptide glossaries.

• Class: glycopeptide antibiotic of the bleomycin family
• Source: fermentation product of a Streptomyces species
• Common synonym: bleomycin A5
• Typical research setting: intralesional or intravascular injection in clinical case series; cell and tumour models in preclinical work
• Not: a short synthetic signalling peptide or a dietary supplement ingredient

How the Term Is Used in Peptide Research

Within peptide literature, "pingyangmycin" is most often encountered as an example of a naturally occurring peptide-derived drug — that is, a molecule whose activity depends on a peptide scaffold produced biologically rather than chemically synthesised. It also appears in glycobiology discussions because of work on carbohydrate modification. Researchers reported that pingyangmycin inhibited glycosaminoglycan sulphation in both cancer cells and tumour tissues, a mechanism separate from the DNA-directed activity classically attributed to bleomycins (PMID 32068946). Outside of that mechanistic niche, the term is used almost entirely in a clinical-procedural sense in the sclerotherapy and dermatology literature.

What the Published Literature Reports

Vascular and lymphatic lesions

The largest cluster of published work concerns vascular anomalies of the head and neck. An early report described treatment of hemangioma in the oral and maxillofacial region using pingyangmycin injection (PMID 12539650). A later series reported that pingyangmycin combined with triamcinolone acetonide was effective for lymphatic malformations in the oral and maxillofacial region (PMID 23257316). Researchers also reported the use of fibrin glue combined with pingyangmycin for embolisation and sclerotherapy of maxillofacial arteriovenous malformations (PMID 32493683), and a 2025 report described ultrasound-guided sclerotherapy with pingyangmycin for periorbital lymphatic malformations (PMID 40448049).

Dermatologic and mucosal lesions

Several dermatology reports have examined intralesional administration. One study described intralesional pingyangmycin treatment for resistant plantar warts (PMID 20051659), and another reported on treatment of xanthelasma palpebrarum with intralesional pingyangmycin (PMID 26890801). In the oral cavity, researchers described sclerotherapy with pingyangmycin for recurrent granulomatous epulis (PMID 28160580). A 2022 study evaluated the clinical efficacy and safety of pulsed dye laser combined with pingyangmycin for hyperplastic scar after acne (PMID 36072572).

Laboratory mechanism work

Preclinical papers have looked at how the compound acts on cells. One study examined the proapoptotic effect and mechanism of action of pingyangmycin on cavernous hemangiomas (PMID 24396428), and a separate report investigated the mechanism of pingyangmycin-induced apoptosis in cultured human umbilical vein endothelial cells (PMID 28510249). In an immuno-oncology context, researchers reported that pingyangmycin enhanced the antitumour efficacy of anti-PD-1 therapy, an effect associated with augmentation of tumour-infiltrating CD8+ T cells (PMID 33388950).

Published Reports at a Glance

Safety and Tolerability: What Studies Report

Safety in the indexed literature is reported at the level of individual clinical series rather than pooled analyses. Safety was an explicit endpoint alongside efficacy in the 2022 study of pulsed dye laser combined with pingyangmycin for hyperplastic scar after acne (PMID 36072572), and the 2025 ultrasound-guided sclerotherapy report for periorbital lymphatic malformations similarly described outcomes of a procedural technique in an anatomically sensitive region (PMID 40448049). Because pingyangmycin is a bleomycin-family antibiotic given by injection in supervised clinical settings, adverse-event profiles in the published record are tied to the specific lesion, route, and combination used in each report; this glossary entry does not reproduce event rates or dosing figures. No dose is stated here, because dose selection in these reports is lesion- and protocol-specific and is documented in the individual papers rather than summarised as a general figure.

Limitations of the Evidence

• Much of the clinical literature consists of single-centre series and case reports rather than large randomised trials.
• Reports frequently combine pingyangmycin with another agent or modality — triamcinolone acetonide (PMID 23257316), fibrin glue (PMID 32493683), or pulsed dye laser (PMID 36072572) — which complicates attribution of effect to the compound alone.
• Mechanistic findings such as inhibition of glycosaminoglycan sulphation (PMID 32068946) and enhancement of anti-PD-1 efficacy (PMID 33388950) come from laboratory and tumour-model work and do not establish clinical outcomes.
• Publication is concentrated geographically, and terminology overlaps with the broader bleomycin literature, which can make direct comparison difficult.

Related Terms

• Bleomycin A5 — the common chemical synonym for pingyangmycin.
• Glycopeptide — the structural class: a peptide backbone bearing carbohydrate groups.
• Sclerotherapy — the procedural category under which most clinical pingyangmycin reports are indexed.
• Glycosaminoglycan sulphation — the carbohydrate-modification pathway examined in mechanistic work (PMID 32068946).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment. Pingyangmycin is a prescription-setting injectable antibiotic studied by clinicians in supervised environments, and nothing here describes how it should be administered.

References

• Proapoptotic effect and the mechanism of action of pingyangmycin on cavernous hemangiomas (Experimental and Therapeutic Medicine, 2014)
• Sclerotherapy for the recurrent granulomatous epulis with pingyangmycin (Medicina Oral Patologia Oral y Cirugia Bucal, 2017)
• Clinical Efficacy and Safety of Pulsed Dye Laser Combined with Pingyangmycin on Hyperplastic Scar after Acne (Mediators of Inflammation, 2022)
• Ultrasound-guided sclerotherapy of pingyangmycin for periorbital lymphatic malformations (BMC Ophthalmology, 2025)
• Pingyangmycin inhibits glycosaminoglycan sulphation in both cancer cells and tumour tissues (Journal of Cellular and Molecular Medicine, 2020)
• Treatment of hemangioma in oral and maxillofacial region with pingyangmycin injection (West China Journal of Stomatology, 2000)
• Pingyangmycin with triamcinolone acetonide effective for treatment of lymphatic malformations in the oral and maxillofacial region (Journal of Cranio-Maxillo-Facial Surgery, 2013)
• Embolization and sclerotherapy of maxillofacial arteriovenous malformations with the use of fibrin glue combined with pingyangmycin (Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020)
• Intralesional pingyangmycin treatment for resistant plantar warts (Dermatology, 2010)
• Mechanism of pingyangmycin-induced apoptosis of cultured human umbilical vein endothelial cells (Genetics and Molecular Research, 2017)
• Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation (Cancer Chemotherapy and Pharmacology, 2021)
• Treatment of Xanthelasma Palpebrarum With Intralesional Pingyangmycin (Dermatologic Surgery, 2016)